Corcept Therapeutics Inc.
Here’s whether Corcept Therapeutics Inc. (CORT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.81% over 10 days); 3-month momentum positive (+26.3%). Concerns: trading below the 200-day MA (long-term downtrend); RSI 79 — overbought, elevated pullback risk; weak 1-year return of -28.1%. Currently 43.5% off its 52-week high. Score: -1/7.
CORT is trading below its 200-day MA ($60.70) — a key warning sign the longer-term trend is under pressure. With an RSI of 79.5, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -28.1% compares to +27.9% for SPY (trailed the market by 55.9%). The current 43.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.